WO2006055352A3 - Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally - Google Patents

Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally Download PDF

Info

Publication number
WO2006055352A3
WO2006055352A3 PCT/US2005/040489 US2005040489W WO2006055352A3 WO 2006055352 A3 WO2006055352 A3 WO 2006055352A3 US 2005040489 W US2005040489 W US 2005040489W WO 2006055352 A3 WO2006055352 A3 WO 2006055352A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipid
methods
platinum compound
treating cancer
administered intraperitoneally
Prior art date
Application number
PCT/US2005/040489
Other languages
French (fr)
Other versions
WO2006055352A2 (en
Inventor
Frank G Pilkiewicz
Roman Perez-Soler
Yiyu Zou
Original Assignee
Transave Inc
Frank G Pilkiewicz
Roman Perez-Soler
Yiyu Zou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transave Inc, Frank G Pilkiewicz, Roman Perez-Soler, Yiyu Zou filed Critical Transave Inc
Priority to AU2005306802A priority Critical patent/AU2005306802A1/en
Priority to MX2007004955A priority patent/MX2007004955A/en
Priority to CA002584673A priority patent/CA2584673A1/en
Priority to EP05851444A priority patent/EP1811963A4/en
Priority to JP2007540183A priority patent/JP5735724B2/en
Publication of WO2006055352A2 publication Critical patent/WO2006055352A2/en
Publication of WO2006055352A3 publication Critical patent/WO2006055352A3/en
Priority to IL182507A priority patent/IL182507A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention relates to a method of treating cancer in a patient comprising administering to the patient intraperitoneally, a cancer treating effective amount of a lipid-­based platinum compound formulation.
PCT/US2005/040489 2004-11-08 2005-11-08 Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally WO2006055352A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2005306802A AU2005306802A1 (en) 2004-11-08 2005-11-08 Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
MX2007004955A MX2007004955A (en) 2004-11-08 2005-11-08 Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally.
CA002584673A CA2584673A1 (en) 2004-11-08 2005-11-08 Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
EP05851444A EP1811963A4 (en) 2004-11-08 2005-11-08 Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
JP2007540183A JP5735724B2 (en) 2004-11-08 2005-11-08 Method for treating cancer using lipid-based platinum compound preparation administered intraperitoneally
IL182507A IL182507A0 (en) 2004-11-08 2007-04-12 Methods of treating cancer with liqid-based platinum compound formulations administered intraperitoneally

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62602904P 2004-11-08 2004-11-08
US60/626,029 2004-11-08
US67159305P 2005-04-15 2005-04-15
US60/671,593 2005-04-15

Publications (2)

Publication Number Publication Date
WO2006055352A2 WO2006055352A2 (en) 2006-05-26
WO2006055352A3 true WO2006055352A3 (en) 2006-07-27

Family

ID=36407625

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/040489 WO2006055352A2 (en) 2004-11-08 2005-11-08 Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally

Country Status (9)

Country Link
US (1) US20060246124A1 (en)
EP (1) EP1811963A4 (en)
JP (2) JP5735724B2 (en)
KR (1) KR20070089693A (en)
AU (1) AU2005306802A1 (en)
CA (1) CA2584673A1 (en)
IL (1) IL182507A0 (en)
MX (1) MX2007004955A (en)
WO (1) WO2006055352A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ296459B6 (en) * 2004-09-14 2006-03-15 Pliva-Lachema A. S. Peroral pharmaceutical composition for targeted transport of platinum complex into colorectal region, process for its preparation, and the composition used as a medicament
US7875288B2 (en) * 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
WO2007117469A2 (en) * 2006-03-30 2007-10-18 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
CZ300424B6 (en) * 2006-06-20 2009-05-13 Pliva - Lachema A. S. Pharmaceutical composition for peroral administration
CZ300590B6 (en) * 2006-06-20 2009-06-24 Pliva - Lachema A. S. Pharmaceutical composition for administration by injection
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US9814672B2 (en) * 2007-03-09 2017-11-14 Susan T. Laing Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi
KR101085203B1 (en) 2011-04-01 2011-11-21 서울대학교산학협력단 Phospholipid nanoparticles for delivery of drugs
DK2892524T3 (en) 2012-09-04 2021-01-25 Eleison Pharmaceuticals LLC PREVENTION OF PULMONAL CANCER RECYCLING WITH LIPID-COMPLEXED CISPLATIN
EA202191228A1 (en) * 2018-11-02 2021-09-24 ТЕЗОРКС ФАРМА, ЭлЭлСи Liposomal intraperitoneal chemotherapy with an increased degree of efficacy
WO2023147640A1 (en) * 2022-02-07 2023-08-10 GERVÁSIO ALVES DA SILVA, Társis Preparation of novel triterpene alcohol derivatives with enhanced bioavailability for cancer, inflammation and pain treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264221A (en) * 1991-05-23 1993-11-23 Mitsubishi Kasei Corporation Drug-containing protein-bonded liposome
US6126966A (en) * 1996-08-23 2000-10-03 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451447A (en) * 1980-03-31 1984-05-29 Bristol-Myers Company Pharmaceutical formulations
US4981692A (en) * 1983-03-24 1991-01-01 The Liposome Company, Inc. Therapeutic treatment by intramammary infusion
USRE33071E (en) * 1983-03-28 1989-09-26 Platinum bound to transferrin for use in the treatment of breast tumors
US4590001A (en) * 1983-03-28 1986-05-20 Stjernholm Rune L Platinum bound to transferrin for use in the treatment of breast tumors
US5019369A (en) * 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
JPH0665648B2 (en) * 1985-09-25 1994-08-24 塩野義製薬株式会社 Stable freeze-drying formulation of platinum anticancer substance
US5041581A (en) * 1985-10-18 1991-08-20 The University Of Texas System Board Of Regents Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5117022A (en) * 1985-10-18 1992-05-26 The Board Of Regents, The University Of Texas System Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5320906A (en) * 1986-12-15 1994-06-14 Vestar, Inc. Delivery vehicles with amphiphile-associated active ingredient
MX9203808A (en) * 1987-03-05 1992-07-01 Liposome Co Inc HIGH DRUG CONTENT FORMULATIONS: LIPID, FROM LIPOSOMIC-ANTINEOPLASTIC AGENTS.
US5616334A (en) * 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
IL83380A (en) * 1987-07-30 1991-04-15 Teva Pharma Stable aqueous cisplatin solutions
DE68901733T2 (en) * 1988-03-04 1993-03-25 Takeda Chemical Industries Ltd LIPOSOME COMPOSITION.
US5141751A (en) * 1988-06-29 1992-08-25 Daiichi Pharmaceutical Co., Ltd. Lipid membrane structures
US5549910A (en) * 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US5756353A (en) * 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5958449A (en) * 1992-12-02 1999-09-28 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for bacterial infections
US5665383A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5780054A (en) * 1996-01-17 1998-07-14 University Of British Columbia Methods for increasing the circulation half-life of protein-based therapeutics
CA2247270A1 (en) * 1996-02-26 1997-08-28 Daiichi Pharmaceutical Co., Ltd. Liposome and liposome dispersion
ES2201296T3 (en) * 1996-04-26 2004-03-16 Genaera Corporation SCALMINE IN COMBINATION WITH OTHER ANTI-BANERIGAN DRUGS FOR TUMOR TREATMENT
US5997899A (en) * 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
US6451784B1 (en) * 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
DE69737510T2 (en) * 1996-12-30 2007-12-06 Battelle Memorial Institute, Columbus Use of an unencapsulated anticancer drug for the preparation of a preparation for the treatment of neoplasms by inhalation
US6630168B1 (en) * 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
US6090407A (en) * 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US6726925B1 (en) * 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
CA2248592A1 (en) * 1998-08-31 2000-02-29 Christopher D. Batich Microspheres for use in the treatment of cancer
ES2156506B1 (en) * 1998-10-14 2002-03-01 Sumitomo Chemical Co METHOD FOR THE PRODUCTION OF PROPYLENE OXIDE.
US20050074499A1 (en) * 1999-03-17 2005-04-07 Mitsubishi Chemical Corporation Ligand-bonded complex
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US6852334B1 (en) * 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
IL146872A0 (en) * 1999-06-03 2002-08-14 Methods and compositions for modulating cell proliferation and cell death
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6800437B1 (en) * 1999-08-06 2004-10-05 Tibotec Bvba Method of monitoring a biological system by labeling with an apo metal binding protein
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
CA2393233A1 (en) * 1999-12-04 2001-06-07 Research Development Foundation Carbon dioxide enhancement of inhalation therapy
US7025988B2 (en) * 2000-02-04 2006-04-11 Lipoxen Technologies Limited Liposomes
US20030124180A1 (en) * 2000-05-02 2003-07-03 Jurgen Ebert Liposomes containing active substances
AU7038501A (en) * 2000-06-30 2002-01-14 Inex Pharmaceuticals Corp Liposomal antineoplastic drugs and uses thereof
EP1355628A2 (en) * 2001-02-01 2003-10-29 Board of Regents, The University of Texas System Stabilised polymeric aerosols for pulmonary gene delivery
JP2004529929A (en) * 2001-04-23 2004-09-30 ニュクリスト ファーマシューティカルズ コーポレーション Use of metals for induction of apoptosis and inhibition of matrix metalloproteinases
ATE322249T1 (en) * 2001-05-18 2006-04-15 Chiron Corp TOBRAMYCIN FORMULATION DELIVERY SYSTEM
WO2003015698A2 (en) * 2001-08-13 2003-02-27 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
EP1424898A4 (en) * 2001-08-20 2008-04-02 Transave Inc Treatment of cancers by inhalation of stable platinum-containing formulations
US20030059375A1 (en) * 2001-08-20 2003-03-27 Transave, Inc. Method for treating lung cancers
JP3415131B1 (en) * 2002-06-03 2003-06-09 メビオファーム株式会社 Liposome preparation
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
MXPA05001312A (en) * 2002-08-02 2005-08-03 Transave Inc Platinum aggregates and process for producing the same.
CA2506749A1 (en) * 2002-11-26 2004-06-10 Gilead Sciences, Inc. Method of drug loading in liposomes by gradient

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264221A (en) * 1991-05-23 1993-11-23 Mitsubishi Kasei Corporation Drug-containing protein-bonded liposome
US6126966A (en) * 1996-08-23 2000-10-03 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally

Also Published As

Publication number Publication date
CA2584673A1 (en) 2006-05-26
US20060246124A1 (en) 2006-11-02
JP5735724B2 (en) 2015-06-17
EP1811963A2 (en) 2007-08-01
WO2006055352A2 (en) 2006-05-26
KR20070089693A (en) 2007-08-31
JP2015098498A (en) 2015-05-28
JP2008519064A (en) 2008-06-05
EP1811963A4 (en) 2010-01-06
MX2007004955A (en) 2007-06-14
AU2005306802A1 (en) 2006-05-26
IL182507A0 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
WO2006055352A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
WO2006099169A3 (en) Novel liposome compositions
WO2007056264A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
MXPA05011208A (en) Topical formulation of ivermectin for the treatment of dermatological conditions.
MY143795A (en) Tetrahydropyridoindole derivatives
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2006113942A3 (en) Method of inhibiting cathepsin activity
WO2007068354A8 (en) Means and methods for the treatment of tumorous diseases
WO2006078463A3 (en) Method for treating cardiovascular disease
WO2006047409A3 (en) Dermal delivery of n-methyl-glucamine and n-methyl-glucamine compounds
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
WO2007056263A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2005092878A3 (en) Schweinfurthin analogues
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2007109093A3 (en) Pyrazolo[1,5-a]pyrimidine derivatives and methods of use thereof
WO2005058934A3 (en) Glycosylated steroid derivatives with anti-migratory activity
WO2004087700A8 (en) Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain
WO2006032525A3 (en) Combinational therapy for treating cancer
WO2008036733A3 (en) Methods for treatment of vesicle transport disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 182507

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2584673

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/004955

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007540183

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200580038178.4

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 3651/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 555360

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005306802

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005851444

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020077013059

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2005306802

Country of ref document: AU

Date of ref document: 20051108

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005306802

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005851444

Country of ref document: EP